Viral Disease News and Research RSS Feed - Viral Disease News and Research

Splice-switching oligonucleotide drugs alter editing of gene transcript

Splice-switching oligonucleotide drugs alter editing of gene transcript

In splice-switching, an innovative therapeutic approach, targeted oligonucleotide drugs alter the editing of a gene transcript to produce the desired form of a protein. [More]
Scientists develop chip for detection of RNA strand of dengue fever virus

Scientists develop chip for detection of RNA strand of dengue fever virus

Scientists at the Center for Research and Advanced Studies (Cinvestav) in Mexico developed a chip (also known as cDNA microarray) that allows detection of the RNA strand of the dengue fever virus. [More]
Cancer drug shows promise in treating blood cell disorders

Cancer drug shows promise in treating blood cell disorders

Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell's natural defenses and efficiently insert disease-fighting genes into the cell's genome. [More]
Study: Sufficient copies of SMN1 gene extend survival in animals with spinal muscular atrophy

Study: Sufficient copies of SMN1 gene extend survival in animals with spinal muscular atrophy

To make up for insufficient amounts of SMN protein, the cause of the inherited neuromuscular disease spinal muscular atrophy (SMA), researchers have successfully delivered a replacement SMN1 gene directly to the spinal cords of animal models of SMA. [More]
S. pneumoniae serotypes differ between primary and post-viral disease

S. pneumoniae serotypes differ between primary and post-viral disease

Certain capsular serotypes of Streptococcus pneumoniae are particularly likely to cause disease in people who have recently experienced a respiratory viral infection, study findings indicate. [More]
Marina Cavazzana, Adrian J. Thrasher honored with Pioneer Award for gene therapy

Marina Cavazzana, Adrian J. Thrasher honored with Pioneer Award for gene therapy

Marina Cavazzana, MD, PhD, Paris Descartes University, France and Adrian J. Thrasher, MD, PhD, University College London Institute of Child Health, UK, have been honored with the Pioneer Award for basic and clinical gene therapy for immunodeficiency disorders. [More]
European Commission invests nearly $475 million in gene transfer and gene therapy projects

European Commission invests nearly $475 million in gene transfer and gene therapy projects

Over the past three funding stages, the European Commission has invested nearly $475 million in 100 projects in the gene transfer and gene therapy field. [More]
Researcher receives Pioneer Award for engineering herpes simplex virus gene delivery systems

Researcher receives Pioneer Award for engineering herpes simplex virus gene delivery systems

​Joseph C. Glorioso, III, PhD (University of Pittsburgh School of Medicine, PA) devoted much of his research career to developing herpes viruses as efficient vectors for delivering therapeutic genes into cells. [More]
Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

Ronald G. Crystal wins Pioneer Award from Human Gene Therapy

In recognition of his seminal work on adenoviral vectors, which accelerated the translation of gene therapy from the research laboratory to the clinic, Ronald G. Crystal, MD (Weill Cornell Medical College, Cornell University, New York City), has received a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Viewpoints: House GOP moves away from health law repeal demands; defeating polio; health website insults Hispanics

Viewpoints: House GOP moves away from health law repeal demands; defeating polio; health website insults Hispanics

Assuming hard-right members of the House don't manage to block it, a $1 trillion appropriations bill is about to be approved by both chambers for the rest of the 2014 fiscal year, through the end of September. [More]
Hepatitis C infection varies widely among different Hispanic groups in the U.S.

Hepatitis C infection varies widely among different Hispanic groups in the U.S.

The first study of hepatitis C infection among different Hispanic groups in the U.S. has found that infection with the virus varies widely, with Puerto Rican Hispanics much more likely than other groups to be infected. The study, led by researchers at Albert Einstein College of Medicine of Yeshiva University, highlights which Hispanic populations would benefit most from increased hepatitis C testing and treatment. [More]
Immunocore, MedImmune sign oncology research collaboration and licensing agreement

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology. [More]
Research findings could help decrease risk of dengue

Research findings could help decrease risk of dengue

A study by an international team of researchers led by Anna M. Stewart Ibarra, Ph.D., of the Center for Global Health and Translational Science at SUNY Upstate Medical University, has provided public health officials with information that will help decrease the risk of dengue, a life-threatening mosquito-borne viral disease that is now one of the fastest spreading tropical diseases globally. [More]
Immunocore achieves first milestone in major research and licensing agreement with GSK

Immunocore achieves first milestone in major research and licensing agreement with GSK

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets. [More]
Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA. [More]
New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
New technology to diagnose influenza quickly

New technology to diagnose influenza quickly

A new technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs slams shut and sick people spread the virus to others, scientists reported here today. In a presentation at the 246th National Meeting & Exposition of the American Chemical Society (ACS), they described how it also could determine the specific strain of flu virus and help select the most effective drug for treatment. [More]
Immunocore, GSK partner for cancer targeting ImmTACs

Immunocore, GSK partner for cancer targeting ImmTACs

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year. [More]
Weather may influence transmission of West Nile, chikungunya, and other viral disease

Weather may influence transmission of West Nile, chikungunya, and other viral disease

Urban epidemics resulting from viral diseases, such as West Nile fever and chikungunya fever, are transmitted by infected mosquitoes. [More]
Columbia University, Chinese Center for Disease Control to open joint pathogen discovery lab in Beijing

Columbia University, Chinese Center for Disease Control to open joint pathogen discovery lab in Beijing

The Center for Infection and Immunity at Columbia University's Mailman School of Public Health and the National Institute for Viral Disease Control and Prevention within the Chinese Center for Disease Control and Prevention will open a Joint Research Laboratory for Pathogen Discovery to conduct surveillance, identify new infectious microbes, establish novel platforms for diagnostics, and develop drugs and vaccines to treat diseases in humans and animals. [More]